Live feed06:45:00·38dPRReleaseLilly's EBGLYSS (lebrikizumab-lbkz) is the first and only selective IL-13 inhibitor to deliver positive Phase 3 outcomes in patients aged six months to 18 years with moderate-to-severe atopic dermatitisLLY· Eli Lilly and CompanyHealth CareOriginal source
